Announces Oversubscribed Private Placement of U.S. $150 Million

Contributed by: Business Wire

Tags

Biotechnology

Pharmaceutical

Alternative Medicine

Finance

General Health

Health

Mental Health

Professional Services

Private Placement

More Like This

Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

CYB003 (12mg dose) demonstrated a rapid and statistically significant reduction in symptoms of depression at three weeks after a single dose, meeting the primary efficacy endpoint (Graphic: Business Wire)

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering